132 related articles for article (PubMed ID: 37005540)
1. N1-Methylnicotinamide: The Mysterious Anti-aging Actor in Renal Transplantation.
Nejabati HR; Roshangar L
Curr Pharm Des; 2023; 29(10):723-731. PubMed ID: 37005540
[TBL] [Abstract][Full Text] [Related]
2. N1-Methylnicotinamide: An Anti-Ovarian Aging Hormetin?
Nejabati HR; Schmeisser K; Shahnazi V; Samimifar D; Faridvand Y; Bahrami-Asl Z; Fathi-Maroufi N; Nikanfar S; Nouri M
Ageing Res Rev; 2020 Sep; 62():101131. PubMed ID: 32711159
[TBL] [Abstract][Full Text] [Related]
3. Urinary Excretion of
Deen CPJ; van der Veen A; Gomes-Neto AW; Geleijnse JM; Borgonjen-van den Berg KJ; Heiner-Fokkema MR; Kema IP; Bakker SJL
J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32041099
[No Abstract] [Full Text] [Related]
4. Nicotinamide N-methyltransferase ameliorates renal fibrosis by its metabolite 1-methylnicotinamide inhibiting the TGF-β1/Smad3 pathway.
Zhang W; Rong G; Gu J; Fan C; Guo T; Jiang T; Deng W; Xie J; Su Z; Yu Q; Mai J; Zheng R; Chen X; Tang X; Zhang J
FASEB J; 2022 Mar; 36(3):e22084. PubMed ID: 35107844
[TBL] [Abstract][Full Text] [Related]
5. Urinary Excretion of
Deen CPJ; Veen AV; Gomes-Neto AW; Geleijnse JM; Berg KJBD; Heiner-Fokkema MR; Kema IP; Bakker SJL
Nutrients; 2020 Jul; 12(7):. PubMed ID: 32664445
[TBL] [Abstract][Full Text] [Related]
6. N1-methylnicotinamide (MNAM) as a guardian of cardiovascular system.
Nejabati HR; Mihanfar A; Pezeshkian M; Fattahi A; Latifi Z; Safaie N; Valiloo M; Jodati AR; Nouri M
J Cell Physiol; 2018 Oct; 233(10):6386-6394. PubMed ID: 29741779
[TBL] [Abstract][Full Text] [Related]
7. Nicotinamide and its metabolite N1-Methylnicotinamide alleviate endocrine and metabolic abnormalities in adipose and ovarian tissues in rat model of Polycystic Ovary Syndrome.
Nejabati HR; Samadi N; Shahnazi V; Mihanfar A; Fattahi A; Latifi Z; Bahrami-Asl Z; Roshangar L; Nouri M
Chem Biol Interact; 2020 Jun; 324():109093. PubMed ID: 32298659
[TBL] [Abstract][Full Text] [Related]
8. Nicotinamide-N-methyltransferase regulates lipid metabolism via SAM and 1-methylnicotinamide in the AML12 hepatocyte cell line.
Yoda M; Mizuno R; Izumi Y; Takahashi M; Bamba T; Kawaoka S
J Biochem; 2023 Jun; 174(1):89-98. PubMed ID: 37014628
[TBL] [Abstract][Full Text] [Related]
9. Urinary Excretion of
Deen CPJ; van der Veen A; van Faassen M; Minović I; Gomes-Neto AW; Geleijnse JM; Borgonjen-van den Berg KJ; Kema IP; Bakker SJL
J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31726722
[TBL] [Abstract][Full Text] [Related]
10. Accumulation of plasma N-methyl-2-pyridone-5-carboxamide in patients with chronic renal failure.
Slominska EM; Smolenski RT; Szolkiewicz M; Leaver N; Rutkowski B; Simmonds HA; Swierczynski J
Mol Cell Biochem; 2002 Feb; 231(1-2):83-8. PubMed ID: 11952169
[TBL] [Abstract][Full Text] [Related]
11. N1-Methylnicotinamide: Is it Time to Consider it as a Dietary Supplement for Athletes?
Nejabati HR; Ghaffari-Novin M; Fathi-Maroufi N; Faridvand Y; Holmberg HC; Hansson O; Nikanfar S; Nouri M
Curr Pharm Des; 2022; 28(10):800-805. PubMed ID: 35152860
[TBL] [Abstract][Full Text] [Related]
12. Protective Effects of N
Miwa T
Front Cell Neurosci; 2021; 15():634868. PubMed ID: 33889076
[TBL] [Abstract][Full Text] [Related]
13. Effect of renal function on homeostasis of asymmetric dimethylarginine (ADMA): studies in donors and recipients of renal transplants.
Said MY; Douwes RM; van Londen M; Minović I; Frenay AR; de Borst MH; van den Berg E; Heiner-Fokkema MR; Kayacelebi AA; Bollenbach A; van Goor H; Navis G; Tsikas D; Bakker SJL
Amino Acids; 2019 Mar; 51(3):565-575. PubMed ID: 30610470
[TBL] [Abstract][Full Text] [Related]
14. N-methyl-2-pyridone-5-carboxamide (2PY)-Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin.
Lenglet A; Liabeuf S; Bodeau S; Louvet L; Mary A; Boullier A; Lemaire-Hurtel AS; Jonet A; Sonnet P; Kamel S; Massy ZA
Toxins (Basel); 2016 Nov; 8(11):. PubMed ID: 27854278
[No Abstract] [Full Text] [Related]
15. Urinary Urea Excretion and Long-term Outcome After Renal Transplantation.
Deetman PE; Said MY; Kromhout D; Dullaart RP; Kootstra-Ros JE; Sanders JS; Seelen MA; Gans RO; Navis G; Joosten MM; Bakker SJ
Transplantation; 2015 May; 99(5):1009-15. PubMed ID: 25393159
[TBL] [Abstract][Full Text] [Related]
16. The age-related increase in N-methyl-2-pyridone-5-carboxamide (NAD catabolite) in human plasma.
Slominska EM; Rutkowski P; Smolenski RT; Szutowicz A; Rutkowski B; Swierczynski J
Mol Cell Biochem; 2004 Dec; 267(1-2):25-30. PubMed ID: 15663182
[TBL] [Abstract][Full Text] [Related]
17. N-methyl-2-pyridone-5-carboxamide: a novel uremic toxin?
Rutkowski B; Slominska E; Szolkiewicz M; Smolenski RT; Striley C; Rutkowski P; Swierczynski J
Kidney Int Suppl; 2003 May; (84):S19-21. PubMed ID: 12694300
[TBL] [Abstract][Full Text] [Related]
18. N1-methylnicotinamide as a possible modulator of cardiovascular risk markers in polycystic ovary syndrome.
Nejabati HR; Samadi N; Roshangar L; Nouri M
Life Sci; 2019 Oct; 235():116843. PubMed ID: 31494172
[TBL] [Abstract][Full Text] [Related]
19. The metabolism of nicotinamide in human liver cirrhosis: a study on N-methylnicotinamide and 2-pyridone-5-carboxamide production.
Pumpo R; Sarnelli G; Spinella A; Budillon G; Cuomo R
Am J Gastroenterol; 2001 Apr; 96(4):1183-7. PubMed ID: 11316167
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
